The Infusion Pumps Market, estimated at USD 11.31 Bn in 2025, is expected to exhibit a CAGR of 8.4% and reach USD 19.89 Bn by 2032.
The industry is witnessing significant growth driven by rising demand for advanced, reliable, and cost-effective medical devices across diagnostic, therapeutic, and monitoring applications. Rapid advancements in device design, digital health integration, and adoption of minimally invasive technologies are reshaping the competitive landscape. Furthermore, supportive regulatory frameworks, increasing healthcare investments, and the growing focus on patient-centric care are expected to create new growth avenues for market players.
Large volume infusion pump segment held dominant position in the global infusion pump market in 2022, accounting for 27.2% share in terms of value, increasing approval and launch of new products is expected to propel growth of the segment during the forecast period.
Market Trends:
Increasing number of surgical procedures is one of the key trends expected to boost the growth of the global infusion pump market. Infusion pumps play a key role in drug administration in surgical patients; are of significant concern to anesthesiologists. Infusion pump, such as elastomeric pumps, are used to administer liquid drugs such as local anesthetics, analgesics, cytostatics, or antibiotics (depending on the therapy). They are designed for continuous drug delivery, on-demand delivery, or combination of both continuous and on-demand drug delivery. Thus, with the increasing number of surgical procedures, the use or demand for infusion pumps is also increasing rapidly. This trend is expected to continue during the forecast period.
Competitive Landscape:
Major players operating in the global infusion pump market include BD, Fresenius Kabi, ICU Medical, Smiths Medical, Medtronic, and B. Braun Melsungen, among others.
Recent Developments:
In September 2022, Insulet announced that the Omnipod 5 system received CE mark clearance, making it available throughout the European Union. It’s cleared for use by adults and children aged two and older with type-1 diabetes.
In August 2022, Baxter International Inc. received the U.S. Food and Drug Administration (FDA) 510(k) clearance of its new Novum IQ syringe infusion pump (SYR) built to help reduce infusion errors and designed to meet rigorous FDA guidance for infusion devices.
Contact Us